文献速递妇科产科

评估卵巢癌新辅助化疗时是否需要静脉血栓栓塞预防:一项文献综述

Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
PubMed 文献 · Gynecol Oncol · 2023-01-24

该文献综述检索PubMed,纳入7项2017至2021年间发表的研究,涉及1427例接受新辅助化疗的晚期卵巢癌、输卵管癌或腹膜癌患者,其中1171例有静脉血栓栓塞(VTE)风险并纳入汇总分析,144例(12.3%)发生VTE。作者认为,接受新辅助化疗的卵巢癌患者可考虑进行VTE预防。

要点

  • 接受新辅助化疗的卵巢癌患者VTE发生率为12.3%(144/1171)。
  • 妇科癌症尤其是卵巢癌的VTE风险不限于术后,新辅助化疗期间风险也升高。
  • 作者认为,接受新辅助化疗的卵巢癌患者可考虑进行VTE预防。

核心结论

  • 作者认为,接受新辅助化疗的卵巢癌患者可考虑进行VTE预防。

研究设计与样本

  • 本文为文献综述,检索PubMed数据库,使用晚期卵巢癌、晚期腹膜癌、晚期输卵管癌、血栓形成、血栓栓塞事件和新辅助化疗等医学术语。
  • 纳入标准为接受新辅助化疗且发生VTE的晚期卵巢癌、输卵管癌或腹膜癌患者;VTE定义为深静脉血栓或肺栓塞。
  • 共纳入7项相关研究,均发表于2017年至2021年间。

主要发现

  • 7项研究共涉及1427例接受新辅助化疗且就诊时已有VTE或治疗期间发生VTE的患者。
  • 其中1171例接受新辅助化疗且有VTE风险的患者纳入汇总分析。
  • 汇总分析中,144例(12.3%)发生VTE。

临床怎么用

  • 作者认为,接受新辅助化疗的卵巢癌患者可考虑进行VTE预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gynecologic cancers, especially ovarian cancer, are associated with a high incidence of venous thromboembolism (VTE). Recent data have shown the risk of VTE development is not only limited to the postoperative period; there also appears to be an increased risk during neoadjuvant chemotherapy (NACT) administration, prompting the need for better risk stratification in this setting. We sought to assess the risk of VTE development in patients with ovarian cancer undergoing NACT. METHODS: We performed a PubMed literature review using the following medical terms: advanced ovarian cancer, advanced peritoneal cancer, advanced fallopian tube cancer, thrombosis, thromboembolic events, and neoadjuvant chemotherapy. Eligible studies included patients with advanced ovarian, fallopian tube, or peritoneal cancer who underwent NACT and had VTE. VTE was defined as either a deep venous thrombosis or a pulmonary embolism. RESULTS: Seven relevant studies were identified; all 7 were published between 2017 and 2021. Across these studies, we identified 1427 patients who underwent NACT and either had VTE at presentation or developed VTE during their treatment course. Of these patients, 1171 underwent NACT and were at risk for VTE development and were included in our pooled analysis. Of these patients, 144 (12.3%) developed VTE. CONCLUSIONS: VTE prophylaxis may be considered in patients with ovarian cancer undergoing NACT.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Moufarrij S, Sassine D, Basaran D, et al. Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review. Gynecol Oncol. 2023. PMID: 36701837. doi:10.1016/j.ygyno.2023.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。